论文部分内容阅读
2001年11月8日,人民大会堂重庆厅里,中国医学科学院药物研究所的科研人员自豪地向世人宣布:我国第一个具有自主知识产权的抗肝炎国家一类新药——百赛诺上市了!终于,中国的肝炎病人可以吃上中国自行研制的治肝炎新药了,中国的创新药物研究和产业化大踏步地向前进了。业内的人部知道,成功创制一个前所未有的新药,国外需要耗资2-3亿美金,费十多年的功夫,而我国的科研工作者们却仅花了不到国外二百分之一的科研经费,就研制成功了百赛诺。这是多大的差距啊。然而,面对成功,百赛诺的主要发明人之一,中国工程院院
On November 8, 2001, in the Chongqing Hall of the Great Hall of the People, researchers at the Institute of Materia Medica, Chinese Academy of Medical Sciences, proudly announced to the world that the first class of new anti-hepatitis drugs in China, Finally, China’s hepatitis patients can avail themselves of the new drug for curing hepatitis developed by China, and China’s innovative drug research and industrialization have made great strides forward. Industry people know that the success of the creation of an unprecedented new drugs, foreign countries need to spend 2-3 billion US dollars, more than 10 years of effort Kung Fu, and our researchers only spent less than one hundred two hundred percent of foreign research Funding, the success of the development of Bai Senuo. This is how much difference ah. However, in the face of success, one of the main inventors of Baiseo, China Academy of Engineering